BGB C354
Alternative Names: BG-C354; BGB-C354Latest Information Update: 14 Jun 2025
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a pre-clinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 05 Jul 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Australia, USA (IV) (NCT06422520)
- 05 Jul 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia, USA (IV) (NCT06422520)